Hemorragia por várices gastroesofágicas en la cirrosis

Similar documents
Variceal hemorrhage is a lethal complication of cirrhosis, particularly

Variceal bleeding. Mainz,

th Annual AISF Meeting 44 th th th, 2011 Rome, February 23 rd -26

Treatment of portal hypertension in the light of the Baveno VI Consensus Conference

Primary Prophylaxis against Variceal Hemorrhage Pharmacotherapy vs Endoscopic Band Ligation

Evidence-Base Management of Esophageal and Gastric Varices

Carvedilol or Propranolol in the Management of Portal Hypertension?

Is pharmacological therapy the best choice for primary prevention of variceal hemmorhaging in patients with hepatic cirrhosis?

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:

Review Article Self-Expandable Metal Stents in the Treatment of Acute Esophageal Variceal Bleeding

Practical Approach to Endoscopic Management for Bleeding Gastric Varices

Beta-blocker plus nitrates for secondary prevention of variceal bleeding (Protocol)

BETA-BLOCKERS IN CIRRHOSIS.PRO.

Michele Bettinelli RN CCRN Lahey Health and Medical Center

Management of variceal bleeding Rachael Harry, MA, MRCP, and Julia Wendon, FRCP

VARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.

Review Article Pathophysiology of Portal Hypertension and Esophageal Varices

Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan

Treatment of portal hypertension

Variceal bleeding in cirrhotic patients

Detection of Esophageal Varices Using CT and MRI

Case Report: Refractory variceal bleeding Christophe Hézode, Henri Mondor Hospital, Paris-Est University, Créteil, France

NONSELECTIVE BETA-BLOCKERS IN PATIENTS WITH CIRRHOSIS: THE THERAPEUTIC WINDOW

CARLO MERKEL, MASSIMO BOLOGNESI, DAVID SACERDOTI, GIANCARLO BOMBONATO, BARBARA BELLINI, RAFFAELLA BIGHIN, AND ANGELO GATTA

Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis

Prevention of the development of varices and first portal hypertensive bleeding episode

MEDICAL PROGRESS. Review Article. N Engl J Med, Vol. 345, No. 9 August 30,

JMSCR Vol 04 Issue 08 Page August 2016

V ariceal haemorrhage is a major cause of mortality and

Original Article INTRODUCTION. pissn eissn X

Hemodynamic effect of carvedilol vs. propranolol in cirrhotic patients: Systematic review and meta-analysis

What Have We Accomplished (and What Lies Ahead)

Risk factors for 5-day bleeding after endoscopic treatments for gastroesophageal varices in liver cirrhosis

Serag Esmat 1 and Dalia Omran 2

Detection of Esophageal Varices in Liver Cirrhosis Using Non-invasive Parameters

Manejo Actual del Sangrado por Varices Gástricas

Prevention and treatment of variceal haemorrhage in 2017

Cost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices

ORIGINAL ARTICLES LIVER, PANCREAS AND BILIARY TRACT

Measurements of portal pressure have wide

Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices

Indications, results and benefits of the measurement of hepatic venous pressure gradient

DAFTAR PUSTAKA. Universitas Sumatera Utara

The role of endoscopy in the management of variceal hemorrhage

A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients

The current recommended prophylaxis of variceal. Long-Term Follow-up of Hemodynamic Responders to Pharmacological Therapy After Variceal Bleeding

Index. Note: Page numbers of article titles are in boldface type.

Portal hypertension is the main complication of cirrhosis

Title: The Baveno VI criteria for predicting esophageal varices: validation in real life practice

Review Article Role of Self-Expandable Metal Stents in Acute Variceal Bleeding

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Are the benefits of beta blockers in cirrhotics only related to decreased portal hypertension?

Beta-blockers in cirrhosis: Cons

Index. Note: Page numbers of article titles are in boldface type.

Chapter 2 Natural History and Stages of Cirrhosis

Portal Hypertension and Variceal Bleeding: An AASLD Single Topic Symposium 1

Complications of portal hypertension (PH) are

CLINICAL MANAGEMENT Loren Laine, M.D. Clinical Management Editor University of Southern California Los Angeles, California

Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage

GI bleeding in chronic liver disease

Transfusion strategies in patients with cirrhosis: less is more. 1. Department of Gastroenterology, Hillingdon Hospital, London, UK

Changes in the Clinical Outcomes of Variceal Bleeding in Cirrhotic Patients: A 10-Year Experience in Gangwon Province, South Korea

ICU Volume 14 - Issue 2 - Summer Matrix

REVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.

PPCR. of Clinical Research A Global Journal in Clinical Research

Terlipressin: An Asset for Hepatologists!

UPPER GASTROINTESTINAL BLEEDING IN LIVER CIRRHOSIS PATIENTS

Original Article. Authors

Barbara Rus Gadžijev Peter Popovič Klinični inštitut za radiologijo UKC Ljubljana

Portal hypertension is the pathophysiologic basis for

Preventing recurrent variceal hemorrhage in

326 Barrera F, et al.,, 2009; 8 (4): presence of esophageal varices. These studies have shown that clinical, biochemical and ultrasonographic

Portal hypertension and gastrointestinal bleeding: Diagnosis, prevention and management

Editorial Process: Submission:07/25/2018 Acceptance:10/19/2018

Portal hypertension Guadalupe Garcia-Tsao, MD

Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis

Variceal bleeding is a major cause of morbidity in patients

ENDOSCOPIC LIGATION OF ESOPHAGEAL VARICES LONG TERM RESULTS

The Value of Renal Artery Resistive Indices: Association with

Care of the Patient With Cirrhosis

Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis

Cyanoacrylate Glue versus Band Ligation for Acute Gastric Variceal Hemorrhage - A randomized controlled trial at Services Hospital, Lahore

Endoscopic management of esophagogastric varices in Japan

Portal Hypertensive Gastropathy and Gastric Antral Vascular Ectasia

A. Purpose and Scope of the Guidance PRACTICE GUIDANCE HEPATOLOGY, VOL. 65, NO. 1, 2017

Rebleeding prophylaxis improves outcomes in patients with. hepatocellular carcinoma. A multicenter case-control study

Comparison between Combination of Band ligation and Propranolol with Propranolol alone in Secondary Prophylaxis of Variceal bleed

Managing Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis

Evaluation of Clinical, Biochemical and Ultrasound Parameters in Diagnosis of Oesophageal Varices

ORIGINAL ARTICLES LIVER, PANCREAS, AND BILIARY TRACT

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding

Cirrhosis is the end stage of any chronic liver

Management of Cirrhosis Related Complications

Gall bladder wall thickening as noninvasive screening parameter for esophageal varices a comparative endoscopic sonographic study

Gastrointestinal bleeding is one of the most important

Pediatric Gastroenterology

Transcription:

Hemorragia por várices gastroesofágicas en la cirrosis Referencias 1. Garcia-Tsao G, Sanyal AJ, Grace ND,Carey W, Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-38. [Erratum, Hepatology 2007;46: 2052.] 2. de Franchis R. Evolving consensus in portal hypertension: report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-76. [Erratum, J Hepatol 2005;43:547.] 3. Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding unresolved issues: summary of an American Association for the Study of Liver Diseases and European Association for the Study of the Liver single-topic conference. Hepatology 2008;47:1764-72. 4. Kovalak M, Lake J, Mattek N, Eisen G, Lieberman D, Zaman A. Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database. Gastrointest Endosc 2007;65:82-8. 5. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61. 6. Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003;38:266-72. 7. D Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis 1999;19:475-505. 8. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med 1988;319:983-9. 9. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet 2003;361:952-4. 10. Villanueva C, Piqueras M, Aracil C, et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006;45:560-7. 11. Abraldes JG, Villanueva C, Banares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol 2008; 48:229-36.

12. Bosch J, Thabut D, Albillos A, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008;47:1604-14. 13. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007;46:927-34. 14. Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology 2007;46:1208-17. 15. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009;49:1245-56. 16. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:Suppl 1:S121-S131. 17. Bosch J, Berzigotti A, Garcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J Hepatol 2008;48:Suppl 1:S68-S92. 18. Schepke M, Werner E, Biecker E, et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001;121:389-95. 19. Gonzalez-Abraldes J, Albillos A, Banares R, et al. Randomized comparison of longterm losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001;121:382-8. 20. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, et al. Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007;46:1040-6. 21. Abraldes JG, Albillos A, Banares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009;136:1651-8. 22. Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002;36:1367-73. 23. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a metaanalysis. Ann Intern Med 1995;123:280-7. 24. Hubmann R, Bodlaj G, Czompo M, et al. The use of self-expanding metal stents to treat acute esophageal variceal bleeding. Endoscopy 2006;38:896-901. 25. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages)

Downloaded from current conceptswhere there once was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2009 November 30 (Epub ahead of print). 26. D Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31. 27. de Franchis R, Eisen GM, Laine L, et al. Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology 2008;47:1595-603. 28. Giannini E, Botta F, Borro P, et al. Platelet count/spleen diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003;52:1200-5. 29. D Amico G, Morabito A. Noninvasive markers of esophageal varices: another round, not the last. Hepatology 2004;39: 30-4. 30. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481-8. 31. Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:923-8. 32. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626-31. 33. Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and longterm prognosis of cirrhosis. Hepatology 2003;37:902-8. 34. D Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-24. 35. Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290-7. 36. Berzigotti A, Gilabert R, Abraldes JG, et al. Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am J Gastroenterol 2008;103:1159-67. [Erratum, Am J Gastroenterol 2008;103:2167.] 37. Bambha K, Kim WR, Pedersen RA, Bida JP, Kremers WK, Kamath PS. Predictors of early re-bleeding and mortality after acute variceal hemorrhage in patients with cirrhosis. Gut 2008;57:814-20.

38. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004;127:476-84. 39. Gluud LL, Klingenberg S, Nikolova D, Gluud C. Banding ligation versus betablockers as primary prophylaxis in esophageal varices: systematic review of randomized trials. Am J Gastroenterol 2007;102:2842-8. 40. Perez-Ayuso RM, Pique JP, Bosch J, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991;337: 1431-4. 41. Casado M, Bosch J, Garcia-Pagan JC, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998;114:1296-303. 42. Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009;50:825-33. 43. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Levy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decade Hepatology 2004;40:652-9. 44. Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 2002;35:609-15. 45. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:1655-61. 46. Fernandez J, Ruiz del Arbol L, Gomez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006;131:1049-56. 47. Cales P, Masliah C, Bernard B, et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med 2001;344:23-8. 48. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004;40:793-801. 49. Garcia-Pagan JC, Caca K, Bureau C, et al. An early decision for PTFE-TIPS improves survival in high risk cirrhotic patients admitted with an acute variceal bleeding: a multicenter RCT. Hepatology 2008;48:Suppl:373A-374A. abstract. 50. Ryan BM, Stockbrugger RW, Ryan JM. A pathophysiologic, gastroenterologic, and radiologic approach to the management of gastric varices. Gastroenterology 2004;126:1175-89.

51. Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001;33:1060-4. 52. Tan PC, Hou MC, Lin HC, et al. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl- 2-cyanoacrylate injection versus band ligation. Hepatology 2006;43:690-7. [Erratum, Hepatology 2006;43:1410.] 53. Lo GH, Liang HL, Chen WC, et al. A prospective, randomized controlled tria of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 2007;39:679-85. 54. Rengstorff DS, Binmoeller KF. A pilot study of 2-octyl cyanoacrylate injection for treatment of gastric fundal varices in humans. Gastrointest Endosc 2004;59:553-8. 55. Garcia-Pagan JC, Villanueva C, Albillos A, et al. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 2009;58:1144-50. 56. Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Banares R, Albillos A. Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 2008;149:109-22. 57. Henderson JM, Boyer TD, Kutner MH, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systemic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006;130:1643-51. 58. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene- coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-75. 59. Ripoll C, Garcia-Tsao G. Treatment of gastropathy and gastric antral vascular ectasia in patients with portal hypertension. Curr Treat Options Gastroenterol 2007;10:483-94. 60. Primignani M, Carpinelli L, Preatoni P, et al. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. Gastroenterology 2000;119:181-7. 61. Sarin SK, Shahi H, Jain M, Jain AK, Issar SK, Murthy NS. The natural history of portal hypertensive gastropathy: influence of variceal eradication. Am J Gastroenterol 2000;95:2888-93. 62. Garcia-Pagan JC, Valla DC. Portal vein thrombosis: a predictable milestone in cirrhosis? J Hepatol 2009;51:632-4. 63. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 2009;49:1729-64.